Assess Reactogenicity and Safety of a Booster of Either Tritanrix [TM]-HepB/Hib-MenAC or Tritanrix [TM]-HepB/Hiberix[TM] Given (Single-blind) at 15-18 (Philippines)/15-24 Mths (Thailand) and a Dose of Mencevax [TM] ACWY at 24-30 Mths (Open Label).

Trial Profile

Assess Reactogenicity and Safety of a Booster of Either Tritanrix [TM]-HepB/Hib-MenAC or Tritanrix [TM]-HepB/Hiberix[TM] Given (Single-blind) at 15-18 (Philippines)/15-24 Mths (Thailand) and a Dose of Mencevax [TM] ACWY at 24-30 Mths (Open Label).

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix) (Primary) ; Hib-DTP-hepatitis B-meningococcal vaccine groups A and C conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 polysaccharide (Primary)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections; Pertussis; Tetanus
  • Focus Adverse reactions; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Oct 2011 Actual end date (Sep 2006) added as reported by ClinicalTrials.gov.
    • 05 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top